REVOLO BIOTHERAPEUTICS
Revolo Biotherapeutics has developed therapies that achieve superior long-term disease remission from less frequent chronic dosing and without suppression of the immune system. Its mission is to revolutionize autoimmune and allergic disease treatment by resetting the immune system for superior long-term disease remission. Revolo Biotherapeutics was founded in 2011 and formerly known as Immune Regulation.
REVOLO BIOTHERAPEUTICS
Industry:
Biotechnology Health Care Life Science
Founded:
2011-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.revolobio.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
52.05 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Google Maps ReCAPTCHA V2 Digital Ocean Gandi.net DNS
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Intarcia Therapeutics
Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Investors List
24 Haymarket
24 Haymarket investment in Series B - Revolo Biotherapeutics
Metellus
Metellus investment in Series B - Revolo Biotherapeutics
Morningside Venture Investments
Morningside Venture Investments investment in Series B - Revolo Biotherapeutics
24 Haymarket
24 Haymarket investment in Series A - Revolo Biotherapeutics
NCL Technology Ventures
NCL Technology Ventures investment in Series A - Revolo Biotherapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2020-03-27 | Immune Regulation Ltd Appoints Jonathan Rigby as Chief Executive Officer |
Official Site Inspections
http://www.revolobio.com Semrush global rank: 4.44 M Semrush visits lastest month: 2.48 K
- Host name: revbio.wpmudev.host
- IP address: 95.179.200.140
- Location: London United Kingdom
- Latitude: 51.5128
- Longitude: -0.0638
- Timezone: Europe/London
- Postal: E1
More informations about "Revolo Biotherapeutics"
Revolo Biotherapeutics Receives Orphan Drug …
Jan 30, 2024 GAITHERSBURG, MD and CAMBRIDGE, UK, January 30, 2024 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term …See details»
Revolo Biotherapeutics Ltd. - Drug pipelines, Patents, Clinical trials ...
For further information, please visit www.revolobio.com. Company ContactWoody Bryan, Ph.D.President and [email protected] Media ContactMichael RubensteinLifeSci …See details»
Revolo Biotherapeutics - Crunchbase Company Profile & Funding
Revolo Biotherapeutics has developed therapies that achieve superior long-term disease remission from less frequent chronic dosing. View contacts for Revolo Biotherapeutics to …See details»
Revolo Biotherapeutics Enters into Partnership Agreement with …
Jun 9, 2021 NEW ORLEANS and LONDON and WALTHAM, Mass. and VILNIUS, Lithuania, June 09, 2021 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the …See details»
Revolo Biotherapeutics Receives Orphan Drug Designation
Jan 30, 2024 [email protected]. Media Contact Monica Rouco Molina, Ph.D. LifeSci Communications +1-929-469-3850 [email protected] ...See details»
Revolo Biotherapeutics Announces the Completion of Phase 1 …
The positive safety profile supports dosing of ‘1104 at higher doses in upcoming Phase 2b trial in EoENEW ORLEANS and CAMBRIDGE, United Kingdom, Sept. 21, 2023 (GLOBE …See details»
Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of …
Topline data anticipated around year-end 2022NEW ORLEANS and LONDON, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company …See details»
Revolo Biotherapeutics Presents New Data for ‘1805 in
Jun 5, 2023 [email protected]. Media Contact Monica Rouco Molina, Ph.D. LifeSci Communications +1-929-469-3850 [email protected] ...See details»
Immune Regulation Announces Rebranding to Revolo
Mar 5, 2021 Revolo Biotherapeutics is developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic disease, …See details»
Revolo Biotherapeutics | About Us
Revolo Biotherapeutics (“Revolo Bio”) has a global footprint, with headquarters in both Gaithersburg, MD, in the US, and London in the United Kingdom. Our team of accomplished …See details»
Revolo Biotherapeutics Announces US FDA Approval of IND …
Jun 23, 2021 NEW ORLEANS and LONDON, June 23, 2021 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset …See details»
Revolo Biotherapeutics | Our Science
In allergic disease, the immune system “overreacts” to antigens. As part of that recognition, a type of immune cell known as a monocyte, interacts with and engulfs these antigens and then …See details»
Revolo Biotherapeutics | New Orleans LA - Facebook
Revolo Biotherapeutics, New Orleans, Louisiana. 506 likes. Revolo Biotherapeutics is developing therapies powered to reset the immune system to achieve...See details»
Immune Regulation Announces Rebranding to Revolo …
Mar 5, 2021 Revolo Biotherapeutics is developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic disease, …See details»
Revolo Biotherapeutics Announces Additional Data from Phase 2a …
Jul 18, 2023 Revolo Biotherapeutics - Data shows statistically significant improvement in patient-reported dysphagia symptoms compared to placebo - - Unique broad mechanistic effect …See details»
Revolo Biotherapeutics Completes Enrollment in Phase 2
Sep 12, 2022 [email protected]. Media Contact Monica Rouco Molina, Ph.D. LifeSci Communications +1-929-469-3850 [email protected] ...See details»
Immune Regulation Announces Rebranding to Revolo …
Mar 5, 2021 For further information, please visit www.revolobio.com. Company ContactMarylyn Rigby, VP Investor Relations & Marketing [email protected] Media Contact Monica …See details»
Revolo Biotherapeutics | Product Development Landscape | '1805
Apr 16, 2024 In preclinical models, ‘1805 demonstrated long-term anti-inflammatory and immunomodulatory effects 5, in addition to a reduction in fibrosis, cartilage destruction, cavity …See details»
Revolo Biotherapeutics | Product Development Landscape | '1104
May 22, 2024 A Phase 2a clinical trial evaluating ‘1104’s efficacy, safety and tolerability met its primary efficacy endpoint with a reduction in the peak eosinophil cell count in the walls of the …See details»